#USA #Deerfield #Baxter #Hemopatch #hemostat

Baxter Introduces the Hemopatch Sealing Hemostat

Baxter International Inc., a leader in the healthcare industry, unveiled its latest innovation, the Hemopatch Sealing Hemostat. This collagen-based product is specifically designed for achieving hemostasis and sealing wounds at room temperature, making it particularly useful in both open and minimally invasive surgical procedures. The introduction of the room-temperature variant marks a significant advancement in tissue healing technology, reinforcing Baxter's commitment to innovative solutions in healthcare.

Steve Wallace, the President of Baxter's Advanced Surgery division, stated, "The Hemopatch Sealing Hemostat represents a major success for Baxter. By launching a room-temperature variant, we underline our ongoing efforts toward advancing tissue healing innovations." Leveraging over a decade of market success, Baxter is excited to present this new product that not only extends shelf life to three years but also simplifies storage requirements for healthcare providers.

Features of Hemopatch

The efficacy of the Hemopatch Sealing Hemostat lies in its unique two-component formulation, which promotes rapid and sustained hemostasis by effectively sealing bleeding surfaces. When applied, the white side of Hemopatch is in direct contact with the tissue and is coated with a thin layer of NHS-PEG. Upon encountering blood or other bodily fluids, the NHS-PEG transforms into a hydrogel that enhances the adhesive properties of the patch and effectively seals the tissue surface.

The interaction with blood stimulates collagen to aggregate platelets. This aggregation leads to a clustering of platelets on the collagen structure, causing them to undergo degranulation and release coagulation factors. These factors, in conjunction with plasma factors, facilitate the formation of fibrin, which is crucial for clot formation.

Moreover, the Hemopatch structure creates a three-dimensional matrix that effectively absorbs fluids while providing increased mechanical stabilization of the clot. Preclinical studies have indicated that the graft is resorbed and replaced by host tissue within approximately six to eight weeks, with minimal tissue reaction.

The rate of resorption and replacement of the damaged tissue with host tissue may vary based on several factors, including the amount of product left in situ and the site of application. The Hemopatch Sealing Hemostat features several clinical benefits, such as tissue sealing, stopping and preventing leaks, and offering rapid and effective hemostasis within two minutes.

Clinical Implications

The introduction of Hemopatch is timed perfectly as healthcare institutions increasingly seek solutions that enhance surgical outcomes while ensuring patient safety. This innovation addresses the growing need for effective hemostatic agents that can function well in a variety of surgical contexts, particularly in emergency and trauma situations where rapid intervention is essential.

For further information regarding indications for use and significant risk information related to the Hemopatch product, viewers can refer to the video provided at the top of this article or visit Baxter's website. Baxter continues its mission to expand healthcare options, and the launch of Hemopatch is a testament to its dedication to improving surgical technologies and patient care.

In summary, Baxter’s Hemopatch Sealing Hemostat offers promising advancements in hemostatic solutions, potentially transforming the approach to wound sealing in various surgical procedures. As healthcare providers familiarize themselves with the product, it may lead to improved surgical outcomes and enhanced patient safety across various surgical disciplines.

For more details about the Hemopatch Sealing Hemostat, please visit Baxter's website.